Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$3.5 million.

  • Adma Biologics' Non Operating Income fell 2104.53% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.2 million, marking a year-over-year increase of 7294.22%. This contributed to the annual value of -$13.3 million for FY2024, which is 7339.34% up from last year.
  • As of Q3 2025, Adma Biologics' Non Operating Income stood at -$3.5 million, which was down 2104.53% from -$2.7 million recorded in Q2 2025.
  • Adma Biologics' 5-year Non Operating Income high stood at -$1.4 million for Q1 2025, and its period low was -$31.9 million during Q4 2023.
  • Moreover, its 5-year median value for Non Operating Income was -$3.5 million (2025), whereas its average is -$5.8 million.
  • In the last 5 years, Adma Biologics' Non Operating Income crashed by 41638.75% in 2023 and then skyrocketed by 8867.56% in 2024.
  • Over the past 5 years, Adma Biologics' Non Operating Income (Quarter) stood at -$3.5 million in 2021, then plummeted by 78.5% to -$6.2 million in 2022, then tumbled by 416.39% to -$31.9 million in 2023, then surged by 88.68% to -$3.6 million in 2024, then rose by 3.13% to -$3.5 million in 2025.
  • Its Non Operating Income stands at -$3.5 million for Q3 2025, versus -$2.7 million for Q2 2025 and -$1.4 million for Q1 2025.